|Articles|July 1, 1998

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
Volume 4
Issue 7 Suppl

What are the Pharmacological Differences Between Angiotensin II Antagonists

Author(s)Thomas Unger, MD

Download PDF: What are the Pharmacological Differences Between Angiotensin II Antagonists

Articles in this issue

almost 28 years ago

Article

Participating Faculty

almost 28 years ago

Article

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

almost 28 years ago

Article

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

almost 28 years ago

Article

Gene Polymorphism Influences Response to Angiotensin Blockade

almost 28 years ago

Article

New Drug Class Offers Benefits in Heart Failure

almost 28 years ago

Article

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

almost 28 years ago

Article

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

almost 28 years ago

Article

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

almost 28 years ago

Article

Clinical Implications of Differences Between Angiotensin II Antagonists

almost 28 years ago

Article

Exploring the Benefits Beyond Blood Pressure Control

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

What are the Pharmacological Differences Between Angiotensin II Antagonists

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Monoclonal Antibodies Had Varying Efficacy in Treating MG